Current therapies for pseudomonas aeruginosa.
Based on the worldwide prevalence of multidrug-resistant strains of Pseudomas aeruginosa and the fact that no newer antipseudomonal agents are available, this article aims to investigate therapeutic solutions for combating infections caused by P aeruginosa, including multidrug-resistant strains. The article focuses mainly on colistin, the re-emerging old antibiotic that possesses prominent antipseudomonal activity in vitro and on doripenem, a newer carbapenem that seems to be close to its global marketing. Regarding older antipseudomonal antibiotics that have been reviewed extensively, only newer aspects on their use are considered in this article.
Giamarellou
Helen
H
Athens University Medical School, Athens, Greece. hgiama@ath.forthnet.gr
Kanellakopoulou
Kyriaki
K
D000900:Anti-Bacterial Agents / Q000493:pharmacokinetics / Q000494:pharmacology / Q000627:therapeutic use*; D015780:Carbapenems / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D003091:Colistin / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use*; D003428:Cross Infection / Q000188:drug therapy* / Q000382:microbiology; D000077726:Doripenem; D024901:Drug Resistance, Multiple, Bacterial; D006801:Humans; D008826:Microbial Sensitivity Tests; D011552:Pseudomonas Infections / Q000188:drug therapy*; D011550:Pseudomonas aeruginosa / Q000187:drug effects* / Q000302:isolation & purification / Q000472:pathogenicity; D016032:Randomized Controlled Trials as Topic
D000900:Anti-Bacterial Agents; D015780:Carbapenems; D000077726:Doripenem; D003091:Colistin